AR056013A1 - Hemifumarato de derivado de piperidina - Google Patents

Hemifumarato de derivado de piperidina

Info

Publication number
AR056013A1
AR056013A1 ARP060103359A ARP060103359A AR056013A1 AR 056013 A1 AR056013 A1 AR 056013A1 AR P060103359 A ARP060103359 A AR P060103359A AR P060103359 A ARP060103359 A AR P060103359A AR 056013 A1 AR056013 A1 AR 056013A1
Authority
AR
Argentina
Prior art keywords
hemifumarate
solvate
piperidine derivative
salt
chlorobenzyl
Prior art date
Application number
ARP060103359A
Other languages
English (en)
Inventor
Bo-Goeran Josefsson
Julien Giovannini
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056013(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR056013A1 publication Critical patent/AR056013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Hemifumarato de N-{2-[((2S)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil}acetamida, o un solvato del mismo, composiciones farmacéuticas que contienen la sal o el solvato y uso de la sal o el solvato en terapias. Reivindicacion 3: El compuesto de acuerdo con la cláusula 2, caracterizado porque exhibe al menos los siguientes picos característicos de difraccion por rayos X de polvo (expresados en grados 2(Theta): a) 6,2, 10,7 y 12,5; o 6,2, 10,7 y 18,8; o c) 6,2, 10,7 y 18,0; o d) 6,2, 10,7, 12,5, 18,0 y 18,8; o e) 6,2, 10,7, 12,5, 18,0, 18,8, 19,7 y 19,8.
ARP060103359A 2005-08-02 2006-08-02 Hemifumarato de derivado de piperidina AR056013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0501769 2005-08-02

Publications (1)

Publication Number Publication Date
AR056013A1 true AR056013A1 (es) 2007-09-12

Family

ID=37708913

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103359A AR056013A1 (es) 2005-08-02 2006-08-02 Hemifumarato de derivado de piperidina

Country Status (16)

Country Link
US (1) US20080176902A1 (es)
EP (1) EP1912944A1 (es)
JP (1) JP2009503066A (es)
KR (1) KR20080031370A (es)
CN (1) CN101238104A (es)
AR (1) AR056013A1 (es)
AU (1) AU2006276346A1 (es)
BR (1) BRPI0614535A2 (es)
CA (1) CA2617406A1 (es)
IL (1) IL188484A0 (es)
MX (1) MX2008001114A (es)
NO (1) NO20081079L (es)
TW (1) TW200734305A (es)
UY (1) UY29713A1 (es)
WO (1) WO2007015668A1 (es)
ZA (1) ZA200800488B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010081034A (ko) * 1998-11-20 2001-08-25 프리돌린 클라우스너, 롤란드 비. 보레르 피페리딘 씨씨알-3 수용체 길항제
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0021670D0 (en) * 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
SE0104251D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
CN101238104A (zh) 2008-08-06
CA2617406A1 (en) 2007-02-08
NO20081079L (no) 2008-02-29
KR20080031370A (ko) 2008-04-08
TW200734305A (en) 2007-09-16
UY29713A1 (es) 2007-02-28
MX2008001114A (es) 2008-03-11
ZA200800488B (en) 2008-12-31
WO2007015668A1 (en) 2007-02-08
EP1912944A1 (en) 2008-04-23
US20080176902A1 (en) 2008-07-24
IL188484A0 (en) 2008-04-13
AU2006276346A1 (en) 2007-02-08
BRPI0614535A2 (pt) 2011-04-05
JP2009503066A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
BRPI0510500A (pt) composições farmacêuticas
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
AR057714A1 (es) Nueva forma cristalina iv de la agomelatina, un procedimiento para su preparacion, y las composiciones farmaceuticas que la contienen
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
CU23515A3 (es) Nuevo proceso para la síntesis y nueva forma cristalina de agomelatina y composiciones farmacéuticas que la contienen
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
BRPI0309457A2 (pt) composições para cuidados pessoais que contém um material contendo zinco em uma composição aquosa de tensoativo.
GT200600518A (es) Derivados de pirimidina
DK1848659T3 (da) Oxygenopfangningssammensætninger og emballage omfattende sammensætningerne
AR059748A1 (es) Nuevas composiciones herbicidas sinergeticas
MY138941A (en) Aryl-pyridine derivatives
IL176988A0 (en) Pharmaceutical compositions containing amino alcohol compounds
PA8638201A1 (es) Forma cristalina alfa del ranelato de estroncio procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BRPI0603197A (pt) composição de toner
AR056013A1 (es) Hemifumarato de derivado de piperidina
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
UY29712A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
BR0312996A (pt) Sal de (s)-pantoprazol e seus hidratos
ECSP088219A (es) Nueva sal i
AR035489A1 (es) 4-fenil-1-(1-fenil-ciclohexil)-1,2,3,6,-tetrahidropiridinas sustituidas, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de estas sustancias para la preparacion de medicamentos
DE602006008797D1 (de) Hibitoren, und pharmazeutische zusammensetzungen, die sie enthalten

Legal Events

Date Code Title Description
FA Abandonment or withdrawal